Literature DB >> 6235073

Defective erythrocyte C3b receptor function associated with low serum complement (C3, C4) concentrations in insulin-dependent diabetes mellitus.

P Ruuska, J Ilonen, A Mustonen, A Tiilikainen.   

Abstract

An immune adherence haemagglutination (IAHA) method was used to measure erythrocyte C3b receptor (EC3bR) activity in 110 patients with insulin-dependent diabetes mellitus (IDDM) and 223 controls. Results obtained from IDDM were correlated with serum complement concentrations (C3, C4) as well as with HLA types of the patients. We observed an increased frequency of defective EC3bR in IDDM (26.4%) compared to controls (10.8%, P less than 0.0005). Those patients who had defective EC3bR (IAHA negative) also had lower serum C3 and C4 concentrations than those with normal EC3bR function (IAHA positive). HLA-Dw3 positive patients had lower C4 concentrations than HLA-Dw3 negative patients and more often had defective EC3bR activity, although this difference was statistically not significant. Our results may indicate the close relationship between the risk factors which predispose to both IDDM and systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235073      PMCID: PMC1536070     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis.

Authors:  R A NELSON
Journal:  Science       Date:  1953-12-18       Impact factor: 47.728

2.  Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G.

Authors:  H Huber; M J Polley; W D Linscott; H H Fudenberg; H J Müller-Eberhard
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

3.  The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

4.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

5.  Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus.

Authors:  J G Wilson; W W Wong; P H Schur; D T Fearon
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

6.  Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus.

Authors:  Y Miyakawa; A Yamada; K Kosaka; F Tsuda; E Kosugi; M Mayumi
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

7.  Lymphocyte blast transformation responses and viral antibodies in relation to HLA antigens in multiple sclerosis.

Authors:  J Ilonen; M Reunanen; A Salmi; A Tiilikainen
Journal:  J Neurol Sci       Date:  1981-01       Impact factor: 3.181

8.  Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG).

Authors:  B Mantovani; M Rabinovitch; V Nussenzweig
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

9.  A receptor for the third component of complement in the human renal glomerulus.

Authors:  M C Gelfand; M M Frank; I Green
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus.

Authors:  K Iida; R Mornaghi; V Nussenzweig
Journal:  J Exp Med       Date:  1982-05-01       Impact factor: 14.307

View more
  1 in total

1.  Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon?

Authors:  P E Ruuska; I Ikäheimo; S Silvennoinen-Kassinen; M L Käär; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.